- Author(s): Patrick Arveux, Stève Bénard, Stéphane Bouée, Antoine Lafuma, Laurent Martin, Ludovic Cravello, Vanessa Rémy, J Gabrielle Breugelmans
, Centre régional de lutte contre le cancer Georges-François Leclerc, 1, rue Professeur-Marion, 21000 Dijon, St[è]ve consultants, 14 rue Grenette, 69002 Lyon, CEMKA Eval, 43 boulevard du Maréchal Joffre, 92340 Bourg-la-Reine, Clinique des Ormeaux, 36, rue Marceau, 76600 Le Havre, Hôpital de la Conception, 147, boulevard-Baille, 13385 Marseille Cedex 05
- Key words: invasive cervical cancer, cost, treatment, human papillomavirus
- Page(s) : 219-24
- DOI : 10.1684/bdc.2007.0198
- Published in: 2007
The objective of this study was to estimate the direct costs of invasive cervical cancer (ICC) management to the French national health insurance system the 1st year after ICC diagnosis. A retrospective survey was conducted in three centres in 2005, including 42 patients admitted for ICC between 2001-2003. Medical records were examined for data relating to treatments and to determine the management costs. To estimate the annual cost of ICC management in France, data were extrapolated to the general population. The number of new ICC cases in France was estimated at 3,247 in 2003. The mean hospitalisation cost increased with ICC severity at diagnosis : 9,164€ for stage I, 15,999€ for stage II, 22,697€ for stage III, and 26,886 € for stage IV. The annual cost associated with the medical management of ICC patients was estimated at 43,862,125€ (sensitivity range 32,973,461€ – 54,748,422€) corresponding to a mean patient cost of 13,509€. Recent HPV vaccination studies have shown 100 % for a quadrivalent (6,11,16,18) HPV vaccine against HPV-induced carcinoma in situ (FIGO stage 0/CIN3), a precursor lesion that may develop into ICC. Thus, it is expected that this vaccine will significantly reduce the socio-economic burden associated with this disease.